Glofitamab stimulates immune cell infiltration of CNS tumors and induces clinical responses in secondary CNS lymphoma

James K Godfrey; Lei Gao; Geoffrey Shouse; Joo Y Song; Stacy Pak; Brian Lee; Bihong T Chen; Avyakta Kallam; John H Baird; Guido Marcucci; Lucy Y Ghoda; Stephanie Vauleon; Alexey V Danilov; Alex F Herrera; Larry W Kwak; Lihua E Budde

doi:10.1182/blood.2024024168

Glofitamab stimulates immune cell infiltration of CNS tumors and induces clinical responses in secondary CNS lymphoma

Blood. 2024 Mar 14:blood.2024024168. doi: 10.1182/blood.2024024168. Online ahead of print.

Authors

Affiliations

¹ City of Hope, Duarte, California, United States.
² City of Hope National Medical Center, Duarte, California, United States.
³ City of Hope Medical Center, Duarte, California, United States.
⁴ Hematologic Malignancies Translational Science, Gehr Family Center for Leukemia Research, City of Hope Medical Center and Beckman Research Institute, Duarte, California, United States.
⁵ Beckman Research Institute, City of Hope, Duarte, California, United States.
⁶ F. Hoffmann-La Roche AG, Basel, Switzerland.

PMID: 38484137
DOI: 10.1182/blood.2024024168

Abstract

Although CD20xCD3 bispecific antibodies are effective against systemic B-cell lymphomas, their efficacy in CNS lymphoma is unknown. Here, we report the CD20xCD3 bispecific, glofitamab, penetrates the blood-brain barrier, stimulates immune-cell infiltration of CNS tumors, and induces responses in CNS lymphoma.

Grants and funding

K12 CA001727/CA/NCI NIH HHS/United States